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Abstract: Fibromyalgia (FM) is a common, complex, and difﬁ  cult to treat chronic widespread 
pain disorder, which usually requires a multidisciplinary approach using both pharmacological 
and non-pharmacological (education and exercise) interventions. It is a condition of heightened 
generalized sensitization to sensory input presenting as a complex of symptoms including pain, 
sleep dysfunction, and fatigue, where the pathophysiology could include dysfunction of the 
central nervous system pain modulatory systems, dysfunction of the neuroendocrine system, 
and dysautonomia. A cyclic model of the pathophysiological processes is compatible with the 
interrelationship of primary symptoms and the array of postulated triggers associated with 
FM. Many of the molecular targets of current and emerging drugs used to treat FM have been 
focused to the management of discrete symptoms rather than the condition. Recently, drugs 
(eg, pregabalin, duloxetine, milnacipran, sodium oxybate) have been identiﬁ  ed that demonstrate 
a multidimensional efﬁ  cacy in this condition. Although the complexity of FM suggests that 
monotherapy, non-pharmacological or pharmacological, will not adequately address the 
condition, the outcomes from recent clinical trials are providing important clues for treatment 
guidelines, improved diagnosis, and condition-focused therapies.
Keywords: fibromyalgia, pain, sleep dysfunction, fatigue, exercise, pharmacological 
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Introduction
Fibromyalgia (FM) is a common chronic widespread pain condition in which patients 
typically present with allodynia and hyperalgesia in addition to experiencing many 
auxiliary symptoms (Table 1) (Wolfe et al 1990; Clauw 1995; Jain et al 2003). The 
American College of Rheumatology (ACR) criteria for the classiﬁ  cation of FM 
established in 1990 require a history of widespread pain for at least 3 months and 
tenderness, determined by a force of 4 kg, in at least 11 of 18 deﬁ  ned tender points 
(Wolfe et al 1990). The presence and severity of FM, which is often reliant on the 
patient’s self-reported symptoms, cannot be determined by objective clinical ﬁ  ndings, 
radiographic abnormalities or routinely used laboratory tests (Mease 2005; Arnold 
2006). Localized or regional pain in most patients with FM precedes the widespread 
pain, which could suggest the latter develops from the former. Although pain is often 
considered the predominant feature, FM is a complex and difﬁ  cult to treat chronic 
condition that usually requires a multidisciplinary approach using both pharmacological 
and non-pharmacological management. Classiﬁ  cation and treatment of FM is often 
further complicated by a waxing and waning course of the symptoms being typical 
and the presence of co-morbid conditions (Table 2).
Many of the symptoms (fatigue, sleep dysfunction, stiffness, depression, 
anxiety, cognitive disturbance) reported in clinical practice in addition to the pain 
and tenderness, however, present a condition with a complexity that is probably 
beyond the ACR 1990 classiﬁ  cation (Katz et al 2006). Nevertheless based upon the 
ACR 1990 criteria, epidemiological studies report prevalence of the condition is Neuropsychiatric Disease and Treatment 2008:4(6) 1060
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2% to 4% of the general population, increasing to greater 
than 7% of those over 70 years of age (Rooks 2007). The 
patient population consists of a female to male ratio of 9:1, 
and the most common age group is 45 to 60 years. Related 
to this, FM has emerged over the past 20 years as a leading 
cause of visits to rheumatologists, either alone or as an 
accompaniment of other rheumatic disorders (Bennett et al 
2007). Although an epidemiological study looks at the 
incidence, distribution, and control of a particular disease in 
a population, the outcomes are dependent on the clarity of 
deﬁ  nition of the condition. The complexity of FM is probably 
responsible for limited epidemiological data and thereby a 
likely underestimation where subjects presenting with FM 
symptoms remain undiagnosed.
A study published in 2003 examined the general health 
status and work incapacity, and views on the effectiveness 
of therapy of patients over a two-year observation period 
(Noller and Sprott 2003). Although there was general satis-
faction with quality of life improvement and health status, 
despite many various treatments received, the patients with 
FM showed no improvement in pain. The authors suggested 
that the positive outcomes and satisfaction was probably the 
result of patient instruction and education of the disease. As a 
consequence of high prevalence, frequent co-morbidities, and 
frustration with current treatment modalities, it is increasingly 
evident that FM represents a signiﬁ  cant challenge (Hoffman 
and Dukes 2008).
Further, symptom expression in FM tends to vary on 
an individual basis, indicative of heterogeneity within the 
condition and the possibility of subgroups of patients with 
FM. Several studies have suggested heterogeneity in the 
presentation of FM with differences in biological variables 
(eg, positive antinuclear antibodies, cytokine abnormalities, 
growth hormone, thyroid hormones) supportive of subgroups 
within the patient population (Bennett 1998; Al-Allaf 
et al 2002; Gur et al 2002; Salemi et al 2003; Metyas et al 
2007). Subgroups based on responses to pharmacological 
interventions and psychosocial responses have also been 
demonstrated (Turk et al 1996; Rossy et al 1999; Wolfe et al 
2000; Lawson 2006a; Lawson 2008).
Management issues
The management of FM has been complicated by the lack of 
a universally accepted pathophysiological mechanism and 
overlap with symptoms of other health conditions (eg, chronic 
fatigue syndrome, myofascial pain, systemic lupus). 
The development of focused and mechanistically based 
therapeutic options targeting the array of symptoms of 
FM has been limited. Current management approaches 
of improving health status in FM use a rehabilitation 
model, rather than a classic biomedical model, integrating 
exercise, education (stress management programs, cognitive 
behavioral therapy (CBT)) and pharmacological treatments 
(Goldenberg et al 2008). Although recommendations 
(eg, European League Against Rheumatism (EULAR), 
American Pain Society (APS)) for FM management have 
been published (Burckhardt et al 2005; Carville et al 2008), 
a universally accepted treatment algorhythm or approach is 
often lacking. A limitation for gaining consensus regarding 
optimal management of FM is that in the many clinical trials 
efﬁ  cacy of the diverse set of treatments has been inconsistent 
with a large proportion of patients not reporting clinically 
signiﬁ  cant outcomes. The guidelines published by EULAR 
and APS provide evidence-based considerations related to 
evaluation and diagnosis of FM, and non-pharmacological 
and pharmacological therapies (Burckhardt et al 2005; 
Carville et al 2008). The evidence regarding effectiveness 
of treatment tended to favor pharmacological studies 
where double blinding and placebo controls were possible. 
Management initially is often drug treatment (which may be as 
a consequence of patient preferences) plus self-management 
advice to pace activities and follow a regular activity program 
Table 1 Symptoms of ﬁ  bromyalgia
Widespread pain
Hyperalgesia and allodynia
Chronic fatigue
Sleep disturbance
Stiffness
Depression
Paresthesias
Cognitive disruption
Exercise intolerance
Table 2 Examples of conditions frequently co-morbid 
with ﬁ  bromyalgia
Chronic low back pain
Irritable bowel syndrome
Depression/anxiety
Temporomandibular joint disorder
Chronic fatigue syndrome
Multiple chemical sensitivities
Interstitial cystitis
Rheumatoid arthritisNeuropsychiatric Disease and Treatment 2008:4(6) 1061
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appropriate to the individual’s need (Hammond and Freeman 
2006; Goldenberg et al 2008).
There has been a rise in the development of new 
interventions for the treatment of FM and a variety of 
outcome measures have been used during clinical trials 
to assess improvement in patients with FM. Partly due to 
issues related to the classiﬁ  cation of FM there often has 
not been uniform agreement as to which domains or which 
assessment tools should be utilized (Mease et al 2007). Often 
assessment of pain is a primary domain of the instrument. 
FM, however, has an impact on functioning in daily life 
from the perspective of the patient, although not all pain 
assessment instruments address these factors. Fatigue in FM 
is considered by patients to be the second most important 
domain after pain and may play a role of relative importance 
in the deterioration of the active state particularly with 
respect to the long duration of the symptom (Mease et al 
2007). Thus, the complexity of this condition may limit in 
clinical practice the potential of a single instrument covering 
the diversity of symptoms of FM raising difﬁ  culties such as 
insensitivity or efﬁ  cacy misinterpretation associated with the 
multidimensionality (Prodinger et al 2008).
Treatment options
Evidence supports exercise and education interventions 
alone and in combination offering beneﬁ  t for people with 
FM (Burckhardt et al 2005; Busch et al 2008; Carville et al 
2008); however, the content and duration of interventions 
and outcomes can be unpredictable. Although the number of 
studies of exercise or behavioral interventions and education 
has increased in the past decade, comparisons are limited 
due to a range of factors such as inconsistent outcome 
measures, assessment tools, small sample size, and high 
attrition rates (Rooks et al 2007). Good outcomes have, 
however, been reported with a number of forms of relaxation 
training including electromyography (EMG) biofeedback, 
heart rate variability (HRV) biofeedback, meditation-based 
stress reduction, tai-chi, and yoga therapy (Drexler et al 
2002; Hammond and Freeman 2006; Hassett et al 2007; 
Goldenberg et al 2008). CBT provides improvements in 
pain-related behavior, coping strategies and overall physical 
function in patients with FM (Turk et al 1998; Nielson and 
Jensen 2004; Bennett and Nelson 2006; Thieme et al 2007). 
Although it has been reported that beneﬁ  t from CBT can 
be maintained for 6 months, the efﬁ  cacy of this form of 
treatment is often found to be inconsistent and, as a single 
treatment modality, CBT does not offer distinct advantage 
over programs of education or exercise (Turk et al 1998; 
Kendall et al 2004; Bennett and Nelson 2006). Pretreatment 
patient characteristics are suggested to be important predic-
tors of the response to CBT and thereby beneﬁ  cial outcomes 
(Turk and Flor 1989; Thieme et al 2007).
Exercise rehabilitation has recently gained increased 
acceptance as a component of the symptom management for 
FM. Modest effects on functional and symptomatic outcomes 
in patients with FM have been reported with supervised 
aerobic exercise training such as cycle ergometry, walking, 
jogging, and water-based activities (Jones et al 2006; Maquet 
et al 2007; Busch et al 2008). These include improvements 
in measures of cardiovascular fitness, Fibromyalgia 
Impact Questionnaire (FIQ) subcales of wellbeing and 
sleep, psychological function, pain-pressure threshold, 
and participant-rated and physician-rated disease severity 
(Mannerkorpi, 2005; Jones et al 2006; Maquet et al 2007; 
Busch et al 2008). The ability to engage in long, continuous 
bouts of activity is often limited by the pain associated with 
FM, therefore alternative systems, such as interval-type 
training are likely to be more appealing and tolerable for 
this patient group. In addition, exercises and activities that 
strengthen the skeletal muscles (eg, stretching) that do not 
cause undue pain are also important for patients with FM 
(Jones et al 2002; Okumus et al 2006; Matsutani et al 2007; 
Bircan et al 2008; Busch et al 2008).
Pharmacological therapies
The pharmacological approach to the management of 
the condition has often been inﬂ  uenced by the debate of 
whether FM is a single entity or a collection of symptoms. 
As a consequence, drug therapy has often focused toward 
the individual symptoms, particularly pain, with current 
pharmacological treatments (Table 3) remaining largely 
empiric (Lawson 2006a; Lawson 2008). The failure of 
anti-inﬂ  ammatory medications, such as the non-steroidal 
anti-inﬂ  ammatory drugs, naproxen and ibuprofen, and pred-
nisone to be effective treatments of FM supports a lack of 
underlying peripheral structural damage and inﬂ  ammatory 
signs (Clark et al 1985; Goldenberg et al 1986; Yanus et al 
1989). A sensory abnormality, with alterations in substance 
P levels, N-methyl-D-aspartate acid (NMDA) receptors and 
mono-aminergic activity within the central nervous system 
(CNS) of patients with FM that would be comparable with 
central sensitization of nociceptive afferent pathways cre-
ating a stimulus-independent pain state has been proposed 
(Desmeules et al 2003; Abeles et al 2007; Martinez-Lavin 
2007). Clinical trials of opioid agonists as treatments of 
FM have been limited and often ineffective. The usefulness Neuropsychiatric Disease and Treatment 2008:4(6) 1062
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of opioids in controlling FM pain may be hindered by the 
suggestion that the opioid systems are maximally activated 
or a decreased availability of central μ-opioid receptors 
results in a reduced efﬁ  cacy in this patient group (Baraniuk 
et al 2004; Harris et al 2007).
Recent studies have emphasized the global state of the 
patient as being an important consideration with quality 
of life outcomes evaluation as an efﬁ  cacy assessment of 
pharmacological therapies. This has identiﬁ  ed the value of 
a number of pharmacological targets in the management 
of FM, in addition to offering insights to aspects of the 
pathophysiology of the condition.
Bioamine modulators
There appears to be a failure in patients with FM to modulate 
pain due to noxious stimuli because of dysfunction in the 
descending inhibitory pain pathways (Kosek and Hansson 
1997; Staud et al 2003; Julien et al 2005). Serotonergic and 
norepinergic neurons in the descending inhibitory system 
that links the periaqueductal gray and the rostal ventromedial 
medulla with the spinal cord are involved in pain regulation 
(Abeles et al 2007). Thus, enhancement of the activity of 
serotonin and norepinephrine within these structures would 
be expected to evoke analgesia.
Often antidepressants, particularly tricyclic antidepressants 
(TCAs) such as amitriptyline and dothiepin, have been 
ﬁ  rst-line pharmacological therapies for FM (Arnold 2006; 
Lawson 2006a). Low-dose TCAs have been signiﬁ  cantly 
effective in the management of sleep, pain, and fatigue in 
patients with FM (Carette et al 1994; Carette et al 1995; 
Richeimer et al 1997; Rao and Clauw 2004; Baker and 
Barkhuizen 2005; Mease 2005; Goldenberg 2007). Inhibition 
of the reuptake of serotonin and norepinephrine into the 
neuronal terminals of the descending tracts by low-dose 
TCAs has been suggested to be responsible for analgesic 
effect of these agents in FM. Although clinically applicable 
improvement in pain (30% reduction) with TCAs was 
observed in randomized controlled trials (RCTs), this was 
often limited to 25% to 45% of FM patients given these 
drugs (Carette et al 1994, 1995; Richeimer et al 1997). The 
limited utility of TCAs as treatments of FM has been related 
to unpredictable responses, adverse effects, and a lack of 
long-term efﬁ  cacy evidence.
The evaluation of selective serotonin reuptake inhibitors 
(SSRIs) in clinical trials with FM patients have shown mixed 
results (Wolfe et al 1994; Anderberg et al 2000; Arnold et al 
2002; Patkar et al 2007). Agents with mixed serotonin and 
norepinephrine activity (eg, ﬂ  uoxetine and paroxetine) have 
demonstrated greater efﬁ  cacy in the management of FM 
than SSRIs with higher speciﬁ  city for serotonin reuptake 
inhibition (eg, citalopram). The conclusion that agents with 
higher selective activity are less consistent as treatments 
of FM is supported by the ﬁ  nding that the combination of 
ﬂ  uoxetine and amitriptyline was more effective (reduced 
pain and FIQ scores, and improved sleep) than either drug 
alone (Goldenberg et al 1996).
New serotonin and norepinephrine reuptake inhibitors 
(SNRIs; eg, duloxetine, milnacipran, venlafaxine) have become 
the focus of recent RCTs (Arnold 2006; Lawson 2006a). 
Duloxetine has a balanced inhibitory proﬁ  le of serotonin 
and norepinephrine reuptake, while milnacipran, similarly to 
amitriptyline, preferentially inhibits norepinephrine reuptake, 
but also exhibits weak NMDA receptor inhibition (Shuto et al 
1995; Stahl et al 2005). Duloxetine signiﬁ  cantly improved 
measures of pain and several measures of quality of life 
(eg, FIQ, Clinical Global Impressions (CGI), Patient Global 
Impression (PGI)) in patients with FM, with and without 
depression (Arnold et al 2004, 2005). The reduction of pain 
and improved quality of life by duloxetine were independent 
of the presence of depression suggesting the symptoms of 
Table 3 Examples of current pharmacological treatments 
of ﬁ  bromyalgia
Tricyclic antidepressants (TCAs)
 amitriptyline
 doxepin
Serotonin-norepinephrine re-uptake inhibitors (SNRIs)
 duloxetine
 milnacipran
 venlafaxine
Selective serotonin re-uptake inhibitors (SSRIs)
  ﬂ  uoxetine
 citalopram
Dopamine agonist
 pramipexole
Anti-epileptics
 pregabalin
 gabapentin
Sedative hypnotics
 zopiclone
 zolpidem
Analgesics
 dihydrocodeine
 morphine
 tramadol
 acetaminophenNeuropsychiatric Disease and Treatment 2008:4(6) 1063
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FM are not related to this mood state. Although duloxetine 
is an effective treatment of FM, this has predominantly been 
observed in female patients and a 50% decrease or greater in 
any pain score was only achieved in up to 41% (dependent on 
the treatment regime) of subjects (Arnold et al 2004, 2005). 
During 6 months of treatment, duloxetine demonstrated dura-
bility with outcomes superior to placebo in the improvement 
of pain and secondary measures such as FIQ, CGI, and Short 
Form 36 (SF-36) scores (Russell et al 2008). Although fatigue 
is a common symptom reported by patients with FM (Mease 
et al 2007), duloxetine failed to improve general or physical 
fatigue during the course of the trial. Interestingly though, a 
signiﬁ  cant improvement was obtained in the mental fatigue 
domain suggesting that duloxetine treatment could improve 
the cognitive dysfunction associated with FM (Russell et al 
2008).
Milnacipran relieves pain symptoms and improves 
measures of quality of life (eg, PGI and FIQ scores) associated 
with FM (Vitton et al 2004; Gendreau et al 2005). A reduction 
of pain by 50% or greater was observed in up to 37% of 
the patient population and a greater improvement in pain 
reduction was recorded in non-depressed subjects treated 
with milnacipran. These ﬁ  ndings are consistent with the 
analgesic effects of milnacipran, like those of duloxetine, 
not being as a consequence of improvement of mood. The 
durable efﬁ  cacy of milnacipran as a treatment of FM has 
been demonstrated in 15-week, 6-month, and 12-month RCTs 
where multidimensional symptom improvement was reported 
(Clauw et al 2007a, b; Goldenberg et al 2007).
The SNRIs, duloxetine and milnacipran, are well tolerated 
because they do not interact with adrenergic, cholinergic, 
or histaminergic receptors, or sodium channels and thereby 
lack many of the adverse effects of TCAs. It is of note, 
however, that insomnia was a frequently reported adverse 
effect for duloxetine in a condition that presents sleep 
dysfunction as a major symptom (Arnold et al 2004, 2005; 
Russell et al 2008).
Therefore, agents that modulate serotonin and norepi-
nephrine are effective treatments for some, but not all, 
patients with FM. Although SNRIs are well tolerated, the 
observation that a signiﬁ  cant number of patients do not gain 
beneﬁ  t from this treatment can question the relationship of 
this mechanism of action and the pathophysiology of FM. 
A critical issue that could be addressed by other SNRIs 
would be the balance of the norepinephrine versus serotonin 
reuptake inhibition. Although modulation of serotonin and 
norepinephrine levels is the primary mechanism of TCAs, 
SSRIs, and SNRIs, these agents act on multiple nociceptive 
targets (eg, NMDA receptors, potassium channels) at central 
and peripheral locations, the contribution of which to the 
clinical outcomes obtained is unknown (Lawson 2002; Mico 
et al 2006). The NMDA receptor antagonists ketamine and 
dextromethorphan have demonstrated efﬁ  cacy (pain score) as 
analgesics in the treatment of FM (Clark and Bennett 2000; 
Graven-Nielsen et al 2000; Cohen et al 2006). Due to a lack 
of speciﬁ  city and thereby associated adverse effects, how-
ever, NMDA receptor antagonists are not widely accepted 
as treatments of chronic pain. Interestingly potassium chan-
nels, whose functional state has been studied in patients with 
ﬁ  bromyalgia, are molecular targets for the management of 
pain (Lawson 2006b; Lawson et al 2008). These molecules 
have been developed to act optimally at sites related to the 
bioamine systems and not at the auxillary targets, which 
could account for the lack of universal effectiveness in this 
patient population.
It is interesting to note that a reduction in pain and an 
improvement in health-related quality of life in patients 
with FM have been demonstrated with tramadol alone, or in 
combination with acetaminophen (Bennett et al 2005). The 
pharmacological properties of tramadol, which is included in 
both the EULAR and APS guidelines for FM management, 
are a mixture of serotonin and norepinephrine reuptake 
inhibition and weak μ-opioid receptor agonism (Frink et al 
1996). The contribution of each of these mechanisms to the 
outcomes obtained with tramadol is unknown.
In addition to norepinephrine and serotonin, dopamine 
plays a role in the descending inhibitory pain pathways at 
the supraspinal level of the thalamus, basal ganglia, and 
limbic cortex (Shyu et al 1992; Chudler and Dong 1995; 
Burkey et al 1999; Lopez-Avila et al 2004). An abnormal 
dopamine response to pain in patients with FM, which may 
be related to prolonged stress, has been reported (Wood et al 
2007a). A disruption of dopaminergic neurotransmission 
being involved in the pathophysiology of FM has been 
further proposed due to a reduction of presynaptic dopamine 
metabolism, demonstrated by positron emission tomography, 
in these patients (Wood et al 2007b). In one RCT, the dopa-
mine D3/D2 receptor agonist pramipexole reduced pain and 
improved fatigue and overall function as indicated by the FIQ 
score in patients with FM with no withdrawals from the study 
because of adverse effects (Holman and Myers 2005). How-
ever, as observed with other pharmacological treatments, 
pramipexole failed to evoke 50% or greater decrease in pain 
in all patients involved in the clinical trial with this efﬁ  cacy 
level only being achieved in 42% of subjects. The patients 
in this trial, however, were taking their current medication, Neuropsychiatric Disease and Treatment 2008:4(6) 1064
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which included opioid analgesics, making the study outcomes 
difﬁ  cult to interpret. Ropinirole, another dopamine D3/D2 
receptor agonist, failed to achieve a signiﬁ  cant therapeutic 
response in patients with FM (Holman 2004); whether the 
lack of efﬁ  cacy of ropinirole is independent of dopamine 
receptor modulation remains to be established.
Alpha2-delta ligands
The release of neurotransmitters that play a role in pain 
processing, such as glutamate and substance P, is regulated 
by calcium inﬂ  ux into nerve terminals within the nociceptive 
pathways (Millan 2002; Dooley et al 2007). Block of the 
presynaptic calcium channels by ligands of the α2δ subunit 
of that channel (eg, gabapentin, pregabalin) will decrease 
the neurotransmitter release and attenuate abnormal 
hyperexcitability of neuronal networks such as that associated 
with chronic pain. Functionally, α2δ-subunit ligands exhibit 
use-dependent properties giving these drugs a signiﬁ  cant 
clinical advantage in that they will be expected to signiﬁ  cantly 
modulate pathological functions related to maintained 
depolarization or hyperexcitability, but only minimally alter 
physiological synaptic function (Dooley et al 2007).
In patients with FM, gabapentin improved pain, FIQ, 
CGI, and PGI scores and sleep quality, however with a high 
incidence of adverse effects (eg, sedation, dizziness) (Arnold 
et al 2007a). Although a 30% or greater reduction in pain score 
was only achieved in 51% of gabapentin-treated patients, 
these ﬁ  ndings support this concept as a therapeutic approach 
to FM. Pregabalin signiﬁ  cantly reduced the pain score and 
improved sleep and fatigue in RCTs (of 8, 13, and 14 weeks) 
involving patients with FM, demonstrating efﬁ  cacy against the 
three major symptoms of the condition (Crofford et al 2005; 
Arnold et al 2007b; Mease et al 2008). Although pregabalin 
monotherapy provides beneﬁ  t in the management of FM as 
demonstrated by signiﬁ  cantly more patients gaining 50% or 
greater improvement in pain with drug treatment than placebo 
treatment, this level of beneﬁ  t was in a limited (up to 30%) 
number of subjects. The number of pregabalin responders only 
increased up to 50% of the subjects when an efﬁ  cacy level 
of 30% or greater decrease in pain scores was determined. 
Further, little additional beneﬁ  t, with an increase in the inci-
dence of adverse effects, was conferred by the highest dose 
(600 mg/day) of pregabalin studied relative to that gained 
with the lower doses (300 and 450 mg/day) suggesting that in 
pregabalin-responders an efﬁ  cacy ceiling was met (Crofford 
et al 2005; Arnold et al 2007b; Mease et al 2008).
The durability of the effects of pregabalin on pain, fatigue, 
and sleep disturbance was demonstrated in a 6-month, 
double-blind, placebo-controlled trial, with an onset of 
beneﬁ  cial effects within 1 week of treatment (Crofford et al 
2008). The durability of the treatment was determined by 
the time to loss of therapeutic response in patients who had 
previously demonstrated improvement in FM symptoms 
with pregabalin. At the end of the trial, 68% of drug-treated 
patients compared to 39% of placebo-treated patients 
maintained therapeutic response related to improvement in 
pain, sleep, fatigue, and functional status. Although more 
pregabalin- than placebo-treated patients discontinued due 
to adverse effects, pregabalin was well tolerated (Crofford 
et al 2008). Pregabalin has recently been approved by the 
FDA for the treatment of FM.
Hypnotics
Sedative hypnotics that modulate benzodiazepine receptors 
(BZD1 and BZD2) located on the GABAA receptor complex 
have been evaluated in patients with FM (Arnold 2006; Lawson 
2006a; Rooks 2007). The benzodiazepines, temazepam, 
alprazolam, and bromazepam, which act non-selectively at 
BZD receptors, have given inconsistent results in clinical 
trials in patients with FM. Although temazepam improved 
sleep quality, no concomitant improvement in pain or fatigue 
symptoms was observed (Hench et al 1989). Thus, a symp-
tomatic beneﬁ  t outcome was evoked by modulation of BZD 
receptors by benzodiazepines rather than management of the 
condition. Although benzodiazepines are useful in conditions 
involving neuronal hyperexcitability (eg, epilepsy, spasticity) 
and would be assumed to have the potential of controlling 
the pain related to the enhanced general sensitization in FM, 
acceptable efﬁ  cacy has not been observed. Zolpidem and 
zopiclone, short-acting non-benzodiazepine hypnotics which 
interact preferentially with the BZD1 receptor, also improved 
sleep in patients with FM, but again failed to improve pain 
(Drewes et al 1991; Grönblad et al 1993; Moldofsky et al 
1996). The failure of modulators of processes within the 
GABAergic inhibitory neurons to provide suppression of 
the symptoms of FM could suggest that the pathophysiology 
does not involve a state of hyperexcitability, but is related to 
an altered threshold of neuronal activation.
Sodium oxybate, the sodium salt of gamma-
hydroxybutyrate (GHB), provided signiﬁ  cant improvements 
in the major symptoms of FM (ie, pain, tenderness, sleep 
quality, and fatigue), which have been largely attributed to its 
capacity to consolidate and improve deep sleep (Russell et al 
2005; Wood 2006). The improvement in pain, at least, being 
related to improved sleep is supported by the outcome of a sig-
niﬁ  cant correlation (r = 0.55, p  0.001) between changes in Neuropsychiatric Disease and Treatment 2008:4(6) 1065
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the pain scale and improvements in sleep quality. The speciﬁ  c 
processes responsible for the sleep disruption in FM are 
unclear. Sleep impacts on pain, fatigue, and social functioning 
(Schaefer 2003; Theadom et al 2007); nevertheless, it is not 
clear whether sleep disturbance is a symptom occurring itself 
or as a co-morbidity. It has been suggested that the relation-
ship between pain and sleep may be bidirectional such that 
pain might increase sleep disturbance and disturbed sleep 
could intensify pain (Afﬂ  eck et al 1996). Whether the patho-
physiology for one symptom is responsible for the initiation 
of another symptom, or a single mechanism is concomitantly 
responsible for more than one symptom still requires deter-
mination. GHB is a precursor to GABA and exhibits agonist 
activity at the GABAB receptor and a postulated GHB-speciﬁ  c 
receptor (Maitre 1997). Data are awaited as to which, if any, 
is the primary mechanism responsible for the effectiveness 
and thereby beneﬁ  cial outcomes with sodium oxybate in the 
management of FM (Mitler and Hayduk 2002).
Pathophysiology
A number of hypotheses have been proposed regarding the 
pathophysiology of FM, which includes a dysfunction of 
pain modulatory systems within the CNS, neuroendocrine 
dysfunction, and dysautonomia (Sarzi-Puttini et al 2006; 
Abeles et al 2007; Arendt Neilsen and Henriksson 2007; 
Tanriverdi et al 2007). FM is often described as a condition 
of heightened generalized sensitization to sensory input 
presenting as a complex of symptoms including pain, 
although lacking signs of underlying peripheral structural 
damage and inﬂ  ammation. A cyclic model of the potential 
interrelationship of the proposed pathophysiological processes 
and the primary symptoms associated with FM is presented 
in Figure 1. Altered processing within the central nociceptive 
system is often proposed to be central to the manifestation 
of the condition and the typically experienced symptoms. 
As a consequence, pain has been described as both a symp-
tom and a contributor of other symptoms such as fatigue, 
impairment of concentration, negative mood, degraded 
sleep, and diminished overall activity (Tuck and Dworkin 
2004). Nevertheless, the nociceptive system is possibly 
one component of a complex network of physiological 
aspects that express a level of interdependence creating 
the clinical proﬁ  le of FM. The cause of the interference in 
pain processing remains unclear, although involvement of 
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chronic psychological stressors, peripheral pain generators, 
and inﬂ  ammatory mediators has been proposed (Bennett 
2005; Abeles et al 2007).
Initiation of altered functioning of the nociceptive system 
has been related to a physical insult, leading to traumatized 
tissue and localized pain, or a psychological insult, such 
as stress (Figure 1) (Aaron et al 1997; Buskila et al 1997; 
Al-Allaf et al 2002; Tishler et al 2006). Sensitization of the 
central nociceptive system occurs due to such a sensory 
input. Central sensitization implies spontaneous nerve 
activity, expanded receptive ﬁ  elds, and abnormal temporal 
summation (or ‘wind-up’) within the spinal cord. NMDA 
receptors, found at the postsynaptic membrane in the dorsal 
horn of the spinal cord, are proposed to play a role in these 
phenomena. Once central (sensitization) hyperexcitability 
has been established, subsequent responses to normal 
stimuli are exaggerated and the threshold for the activation 
of new inputs is reduced. Central to a variety of neuronal 
processes, including synaptic plasticity and neurotoxicity, 
is the activation of NMDA receptors by glutamate leading 
to a rise in intracellular calcium and the initiation of second 
messenger pathways that mediate long-term potentiation 
(enduring enhancement of synaptic transmission after the 
initiating stimulus has ceased) (MacDermott et al 1986; 
Thomas 1995; Ressler et al 2002). In addition, nitric oxide 
production by neuronal nitric oxide synthase is induced by 
the calcium inﬂ  ux, which is believed to evoke a retrograde 
signaling action enhancing presynaptic glutamate release 
(DeMaria et al 2007). Studies on levels of nitric oxide in 
FM, however, have not been conclusive (Ozgocmen et al 
2006). Similarly substance P, a peptide neurotransmitter 
associated with pain transmission, in addition to many other 
actions enhances the responsiveness of NMDA receptors to 
glutamate (DeMaria et al 2007). Although elevated levels 
of substance P in the cerebrospinal ﬂ  uid of patients with 
FM have been reported (Vaerøy et al 1988; Russell et al 
1994), such observations have not been conﬁ  rmed in other 
studies. In patients with ﬁ  bromyalgia temporal summation of 
nociceptive stimuli (where the intensity of rapidly repeated 
noxious stimuli is perceived to increase) is enhanced and 
diffuse noxious inhibitory control is reduced (Lautenbacher 
and Rollman 1997; Staud et al 2003; Julien et al 2005).
Studies utilizing neuroimaging techniques such as func-
tional magnetic resonance imaging (fMRI), and single photon 
emission computed tomography (SPECT) have demonstrated 
that patients with FM exhibit neural activity in regions 
involved in processing the sensory pain sensation, in response 
to the administration of a noxious pressure or heat stimulus, 
that differs from that observed in health controls (Williams 
and Gracely 2006; Guedj et al 2007a). Although both patients 
with FM and healthy controls detect and experience a full 
range of perceived pain stimuli, the stimulus intensity thresh-
old of the former group is signiﬁ  cantly lower. The status of 
neural activity in the patients with FM was related to physi-
ological and not psychological stimuli as mood states, such 
as depression, did not appear to inﬂ  uence the outcome. Data 
from SPECT neuroimaging studies have also been predictive 
of therapeutic responsiveness of treatment of patients with 
FM with amitriptyline and ketamine (Adiguzel et al 2004; 
Guedj et al 2007b). It is important to recognize that such neu-
roimaging techniques do not measure neural activity directly, 
but infer activity from localized changes in regional cerebral 
blood ﬂ  ow occurring in response to neural metabolic demand. 
Further work is required to determine whether these observa-
tions are related to neural demand inﬂ  uencing vascular status 
or whether a compromised vasculature, due to dysautonomia, 
is impacting on neural activity, or a combination of both. 
Neuroimaging has focused on the pain dimension of FM, 
where other symptoms such as fatigue and disturbed sleep 
have a signiﬁ  cant role, as do non-noxious stimuli such as 
auditory and tactile (Geisser et al 2008).
The intensity and duration of the insult, and thereby 
pain, required to achieve the level of sensitization related 
to FM is not understood. Data from genetic studies could 
indicate a familial predisposition in vulnerable subjects 
to the development of FM (Buskila and Sarzi-Puttini 
2006). Although the frequency of polymorphisms of the 
serotonin transporter promoter gene, 5-HT2A receptor 
gene, catechol-O-methyltransferase gene, and dopamine 
D4 receptor gene is changed in patients with FM, the 
relevance to the etiology and pathophysiology is unknown 
(Bondy et al 1999; Offenbaecher et al 1999; Cohen et al 
2002; Gursoy et al 2003; Buskila et al 2004). Consequently 
what would be an innocuous event in the majority of the 
people has a marked outcome in 2%–4% of the population.
In addition to increasing the sensitivity of the central 
nociceptive system the sensory inputs appear to lead 
to activation of circuits of the limbic system such as 
the autonomic nervous system and the neuroendocrine 
hypothalamic pituitary adrenal (HPA) axis (Figure 1). HPA 
axis dysfunction in patients with FM is characterized by 
elevated cortisol levels lacking diurnal ﬂ  uctuation with 
blunted secretion in response to stress (Abeles et al 2007; 
Tanriverdi et al 2007). This is consistent with the HPA axis 
being underactivated to stimuli and some patients with FM 
exhibiting a subnormal adrenocortical function. There are Neuropsychiatric Disease and Treatment 2008:4(6) 1067
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no structural abnormalities in the endocrine glands of the 
HPA axis and current data do not allow an explanation 
of the location of the defect of the HPA dysfunction. 
Dysautonomia has also been suggested to be responsible 
for the generation and maintenance of the symptoms of FM 
(Martinez-Lavin 2007). Selective sympathetic blockade 
with guanethidine in patients with FM leads to a reduction 
in pain and number of tender points with restoration of the 
symptoms by norepinephrine injections (Backman et al 
1988; Martinez-Lavin 2004). An increased sympathetic 
and decreased parasympathetic activity in patients with FM 
resulting in a persistently hyperactive sympathetic nervous 
system that is hyporeactive in response to stress has been 
reported (Martinez-Lavin et al 1997; Martinez-Lavin et al 
1998; Cohen et al 2000). Chronic hyperstimulation of the 
α-adrenergic receptors of the sympathetic nervous system 
could lead to receptor desensitization and downregulation. 
The augmented sympathetic activity appears to be greater in 
women than men, suggesting that women with FM may have 
more severe autonomic dysfunction. Although TCAs and 
SNRIs, through modulation of bioamine levels, may achieve 
beneﬁ  t in the treatment of FM by an effect on descending 
pain pathways, the lack of tolerance or efﬁ  cacy of these drugs 
may be associated with an augmentation of the sympathetic 
component of the dysautonomia.
FM patients demonstrate signiﬁ  cant variability in stress 
reactivity and the different response patterns related to 
potential autonomic response speciﬁ  city (Turk and Flor 
1989; Thieme et al 2006). The activation of the processes 
related to the limbic circuits in patients with FM appears to 
express an increased sensitivity to stressors perhaps due to 
the altered functioning preventing a normal physiological 
regulation of such an event and thereby exacerbation of 
certain systems. For example the limbic system, HPA axis, 
and autonomic nervous system activation could be related 
to mood arousal resulting in altered sleep architecture and 
enhanced anxiety leading to depression. Such outcomes 
within the limbic system may also be related to the memory 
and cognitive function, and mental fatigue (ﬁ  brofog) in 
patients with FM (Goldenberg et al 2008). The blunted 
sympathetic activity to stress and impaired parasympathetic 
modulation of the dysautonomia may also be associated 
with the prevalence of symptoms such as syncope, morning 
stiffness, pseudo-Raynaud’s phenomenon, and intestinal 
irritability observed in this patient population (Sarzi-Puttini 
et al 2006; Martinez-Lavin 2007).
Stress has central hyperalgesic effects that could be due to 
a direct central nociceptive system or an indirect peripheral 
action. The enhanced peripheral sympathetic nervous system 
tone related to the dysautonomia will, for example, lead to 
generalized widespread peripheral vasoconstriction (in addi-
tion to other autonomic responses). As a consequence of an 
associated reduced blood ﬂ  ow, a relatively mild challenge 
(eg, stretching, light exercise) to the skeletal muscle can 
evoke a state of ischemia and changed muscle energy 
metabolism. Low levels of phosphocreatine and ATP at rest, 
low phosphorylation potential, and total oxidative capacity, 
and a reduced number and size of mitochondria in skeletal 
muscle of patients with FM have been identiﬁ  ed (Bengtsson 
et al 1986; Bartels and Danneskiold-Samsøe 1988; Jubrias 
et al 1994; McIver et al 2006). Such a vascular event would 
cause the sensitization of ergoreceptors, with the potential 
outcome of muscle fatigue, and the sensitization or activation 
of nociceptors leading to multifocal muscular pain and hyper-
algesia well beyond the area of the initial physical insult. 
The generalized sensitization to pain within skeletal muscle 
will be associated with spatially distributed allodynia and 
hyperalgesia (tender points). Therefore, changes in peripheral 
factors, especially in intramuscular microcirculation and in 
muscle energy metabolism, could act as excitatory triggers 
for the alterations in the nociceptive system in the CNS and 
for multifocal pain in the muscles (Henriksson 1999; Abeles 
et al 2007). The activation of the nociceptors leading to fur-
ther activation of the central nociceptive system will complete 
a loop within the processes related to the pathophysiological 
mechanisms of FM (Figure 1).
The potential of development of cyclic processes enables 
a trigger (eg, tender points, tissue trauma, exercise, stress) at 
any point within the loop to initiate and express (to varying 
degrees) the array of symptoms typical of FM. Evidence 
suggests patients with FM exhibit greater sensitivity to a 
range of sensory stimuli including auditory, tactile, heat, and 
pressure (Geisser et al 2003; Carrillo-de-la-Pena et al 2006; 
Montoya et al 2006; Geisser et al 2008). The heightened 
responsiveness to sensory stimulation may be related to a 
lack of inhibitory control over repetitive or irrelevant somato-
sensory stimulation (Geisser et al 2003; Carrillo-de-la-Pena 
et al 2006; Montoya et al 2006; Geisser et al 2008). These 
ﬁ  ndings are consistent with FM being in part due to a global 
disturbance in sensory processing rather than an isolated 
abnormality in pain processing.
Conclusion
FM is a common, complex, and difﬁ  cult to treat chronic 
widespread pain disorder, which usually requires a 
multidisciplinary approach using both pharmacological Neuropsychiatric Disease and Treatment 2008:4(6) 1068
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and non-pharmacological interventions. It is described as a 
condition of heightened generalized sensitization to sensory 
input presenting as a complex of symptoms including pain, 
where the pathophysiology could include dysfunction 
of the CNS pain modulatory systems, dysfunction of the 
neuroendocrine system, and dysautonomia. Current data 
do not allow an understanding of the exact locations of the 
defects in these systems. In addition, whether aspects of 
the proposed pathophysiology are causal or consequential 
requires clariﬁ  cation. A cyclic model of the pathophysi-
ological processes is compatible with the interrelationship 
of primary symptoms and the array of postulated triggers 
associated with FM.
Although a variety of treatment modalities have been utilized 
in the management of FM, an effective (50% of the patient 
population gaining beneﬁ  t) means of therapy is still awaited. 
Treatments have demonstrated an improvement in health status 
in a proportion of patients with FM in clinical trials; however, 
these ﬁ  ndings require conﬁ  rmation in usual-care settings of the 
subjects. Many of the molecular targets of current and emerging 
drugs used to treat FM have been focused to the management of 
discrete symptoms rather than the condition. Drugs (eg, prega-
balin, duloxetine, milnacipran, sodium oxybate) have now been 
identiﬁ  ed that demonstrate a multidimensional efﬁ  cacy in this 
condition. The large percentage of patients who are refractory 
to these treatments during RCTs, makes it difﬁ  cult to determine 
the relationship of the primary mechanism of action of the 
drugs to the pathophysiology of FM. Although the complexity 
of FM suggests that monotherapy, non-pharmacological or 
pharmacological, will not adequately address the condition, 
the outcomes from recent clinical trials are providing important 
clues for treatment guidelines, improved diagnosis, and con-
dition-focused therapies. Finally, the diversity of the biology 
related to FM and the variability in responsiveness to treatments 
is consistent with the existence of subgroups of patients with 
potentially differing pathophysiology.
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